Gensciences (Shengsi Biopharma) is at the forefront of developing innovative therapies for hemophilia, focusing on long-acting recombinant coagulation factors. Their lead product, FRSW107, is a novel extended half-life factor VIII Fc fusion protein designed for the prophylactic and on-demand treatment of severe hemophilia A. This product has shown promising results in clinical trials, demonstrating significant reductions in annualized bleeding rates and joint bleeding rates, while maintaining a favorable safety profile. Gensciences is also advancing SS109, the world's first ultra-long-acting recombinant activated factor VII, which has exhibited a prolonged half-life and improved hemostatic efficacy compared to existing treatments.

Additionally, Gensciences is developing SS315, a bispecific antibody that mimics the activity of factor VIIIa, aimed at addressing the needs of hemophilia A patients, particularly in developing countries where access to existing therapies may be limited. The company leverages a proprietary long-acting biotechnology platform to create these therapies, with a commitment to meeting the unmet clinical needs of hemophilia patients. With multiple products in various stages of clinical development, Gensciences aims to provide innovative solutions that enhance the quality of life for individuals living with hemophilia.

China

Gensciences, also known as Shengsi Biopharma, is an innovative biopharmaceutical company based in Nantong, China. The company is privately held and has received venture capital backing. Gensciences is dedicated to improving the lives of people living with hemophilia and has received hundreds of millions of yuan in Series D financing. The company's innovative development strategy focuses on drug pipelines, patents, and clinical trials for hemic and lymphatic diseases. For more information, you can visit their official website at http://shengsi.haio.cn/index.html.

Gensciences (Shengsi Biopharma)

Company Details